Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Apr;47(4):924-6.
doi: 10.1128/JCM.01842-08. Epub 2009 Feb 9.

Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer

Affiliations
Comparative Study

Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer

R O Phillips et al. J Clin Microbiol. 2009 Apr.

Abstract

In a previous study, we reported that the sensitivity of PCR targeting the IS2404 insertion sequence of Mycobacterium ulcerans was 98% when it was applied to 4-mm punch biopsy samples of Buruli lesions. Fine-needle aspiration (FNA) is a less traumatic sampling technique for nonulcerated lesions, and we have studied the sensitivity of PCR using FNA samples. Fine-needle aspirates were taken with a 21-gauge needle from 43 patients diagnosed clinically with M. ulcerans disease. Four-millimeter punch biopsies were obtained for microscopy, culture, and PCR targeting the IS2404 insertion sequence. The sensitivity of PCR using samples obtained by FNA was 86% (95% confidence interval [95% CI], 72 to 94%) compared with that for PCR using punch biopsy samples. In this study, the sensitivities of culture and microscopy for punch biopsy samples were 44% (95% CI, 29 to 60%) and 26% (95% CI, 14 to 41%), respectively. This demonstrates that PCR on an FNA sample is a viable minimally invasive technique to diagnose M. ulcerans lesions.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Amofah, G., S. Asamoah, and C. Afram-Gyening. 1998. Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop. Doct. 2881-83. - PubMed
    1. Asiedu, K., and R. M. Scherpbier (ed.). 2000. Buruli ulcer: Mycobacterium ulcerans infection. WHO/CDS/CPE/GBUI/2000.1. World Health Organization, Geneva, Switzerland.
    1. Buntine, J., and K. E. Crofts. 2001. Buruli ulcer: management of Mycobacterium ulcerans disease. A manual for health care providers. World Health Organization, Geneva, Switzerland. http://www.who.int/gtb-buruli/publications/index.html.
    1. Chauty, A., M. F. Ardant, A. Adeye, H. Euverte, A. Guedenon, C. Johnson, J. Aubry, E. Nuermberger, and J. Grosset. 2007. Promising clinical efficacy of the combination streptomycin-rifampin for the treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 514029-4035. - PMC - PubMed
    1. Debacker, M., J. Aguiar, C. Steunou, C. Zinsou, W. M. Meyers, and F. Portaels. 2005. Buruli ulcer recurrence, Benin. Emerg. Infect. Dis. 11584-589. - PMC - PubMed

LinkOut - more resources